Japanese and Caucasian Volunteers 2 3

[1]  H. Loetscher,et al.  Comprehensive in vitro pharmacological selectivity profile of oseltamivir prodrug (Tamiflu®) and oseltamivir active metabolite , 2008 .

[2]  Yoko Ihama,et al.  Analysis of oseltamivir active metabolite, oseltamivir carboxylate, in biological materials by HPLC-UV in a case of death following ingestion of Tamiflu. , 2008, Legal medicine.

[3]  H. Kusuhara,et al.  P-glycoprotein Restricts the Penetration of Oseltamivir Across the Blood-Brain Barrier , 2008, Drug Metabolism and Disposition.

[4]  T. Fujita,et al.  Oseltamivir (Tamiflu) Efflux Transport at the Blood-Brain Barrier via P-Glycoprotein , 2008, Drug Metabolism and Disposition.

[5]  W. A. Blumentals,et al.  The safety of oseltamivir in patients with influenza: analysis of healthcare claims data from six influenza seasons. , 2007, MedGenMed : Medscape general medicine.

[6]  Kazuyoshi Watanabe,et al.  Serum levels of cytokines and EEG findings in children with influenza associated with mild neurological complications , 2007, Brain and Development.

[7]  Jerome J. Schentag,et al.  Similarity in Pharmacokinetics of Oseltamivir and Oseltamivir Carboxylate in Japanese and Caucasian Subjects , 2007, Journal of clinical pharmacology.

[8]  C. Chiu,et al.  NEUROLOGIC MANIFESTATIONS IN CHILDREN WITH INFLUENZA B VIRUS INFECTION , 2006, The Pediatric infectious disease journal.

[9]  A. Okumura,et al.  Oseltamivir and delirious behavior in children with influenza. , 2006, The Pediatric infectious disease journal.

[10]  T. Ishikawa,et al.  Genetic polymorphisms of ATP-binding cassette transporters ABCB1 and ABCG2: therapeutic implications , 2005, Expert opinion on pharmacotherapy.

[11]  A. Moscona.  Neuraminidase inhibitors for influenza. , 2005, The New England journal of medicine.

[12]  H. Mohrenweiser,et al.  Functional Consequences of Single Nucleotide Polymorphisms in the Human Organic Anion Transporter hOAT1 (SLC22A6) , 2005, Journal of Pharmacology and Experimental Therapeutics.

[13]  Kazuyoshi Watanabe,et al.  Delirious behavior in children with influenza: its clinical features and EEG findings , 2005, Brain and Development.

[14]  Conrad C. Huang,et al.  Functional analysis of polymorphisms in the organic anion transporter, SLC22A6 (OAT1) , 2005, Pharmacogenetics and genomics.

[15]  T. Abe,et al.  Involvement of Multiple Transporters in the Efflux of 3-Hydroxy-3-methylglutaryl-CoA Reductase Inhibitors across the Blood-Brain Barrier , 2004, Journal of Pharmacology and Experimental Therapeutics.

[16]  R. Kim,et al.  Pharmacogenomics of the OATP and OAT families. , 2004, Pharmacogenomics.

[17]  Danny D Shen,et al.  Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics. , 2004, Advanced drug delivery reviews.

[18]  P. Ward,et al.  Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis. , 2004, The Journal of infectious diseases.

[19]  T. Ishikawa,et al.  Functional evaluation of ABCB1 (P-glycoprotein) polymorphisms: high-speed screening and structure-activity relationship analyses. , 2004, Drug metabolism and pharmacokinetics.

[20]  H. Kusuhara,et al.  Contribution of Organic Anion Transporter 3 (Slc22a8) to the Elimination of p-Aminohippuric Acid and Benzylpenicillin across the Blood-Brain Barrier , 2003, Journal of Pharmacology and Experimental Therapeutics.

[21]  Yhu-Chering Huang,et al.  Influenza A-associated central nervous system dysfunction in children presenting as transient visual hallucination. , 2003, The Pediatric infectious disease journal.

[22]  V. Zarotsky,et al.  Safety and Tolerability of Serial Cerebrospinal Fluid (CSF) Collections During Pharmacokinetic/Pharmacodynamic Studies: 5 Years Experience , 2003 .

[23]  M. Tapia,et al.  Influenza B infection associated with encephalitis: treatment with oseltamivir. , 2002, The Pediatric infectious disease journal.

[24]  P. Ward,et al.  The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[25]  P. Ward,et al.  Long‐Term Use of Oseltamivir for the Prophylaxis of Influenza in a Vaccinated Frail Older Population , 2001, Journal of the American Geriatrics Society.

[26]  P. Ward,et al.  Oral oseltamivir treatment of influenza in children , 2001, The Pediatric infectious disease journal.

[27]  W. Herron,et al.  Development of a high-performance liquid chromatographic-mass spectrometric assay for the specific and sensitive quantification of Ro 64-0802, an anti-influenza drug, and its pro-drug, oseltamivir, in human and animal plasma and urine. , 2000, Journal of chromatography. B, Biomedical sciences and applications.

[28]  S. Trottier,et al.  Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial , 2000, The Lancet.